INDP Indaptus Therapeutics, Inc.
USHealthcareAs of 2026-07-02
Why INDP matters now
Indaptus Therapeutics, Inc. (INDP) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.03 with +3.06% on the session and $5.3M in market capitalization; recent performance reads 1-month +193.23% and YTD +34.02%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.5M, and EPS of $-1.17. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -252.9%.
The latest indexable market news headline is "Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Lu Qinglai filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
6.77
P/S
0.00
EV/EBITDA
-0.28
DCF Value
$8.30
FCF Yield
-252.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1028.8%
ROA
-864.7%
ROIC
-1396.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.5M | $-1.17 |
| Q4 2025 | $0.00 | $-8.1M | $-3.74 |
| FY 2025 | $0.00 | $-20.8M | $-21.58 |
| Q3 2025 | $0.00 | $-3.0M | $-0.52 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.27
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.